Id Biomedical Corporation

Id Biomedical Corporation of Quebec

Biochem Pharma Inc.

Clement Rioux

Bernard R Brodeur

Denis Martin

Josee Hamel

George H Lowell

David Hugh Jones

David S Burt

Josée Hamel

Nathalie Charland

Joseph J Zimmermann

Isabelle Pineau

Martine Boyer

Isabelle Charlebois

Gregory Lee White

Gregory L White

David Jones

David H Jones

Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).

Compositions and methods for activating innate and allergic immunity

Group B(GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

[object Object]

proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

The identification of a highly conserved, immunologically accessible antigen at the surface offacilitates treatment, prophylaxis, and diagnosis ofdiseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from threestrains and from onestrain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of thesurface protein, and antibodies that bind to this protein are also disclosed.

An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.

Proteosome-liposaccharide vaccine adjuvant

The identification of a highly conserved, immunologically accessible antigen on the surface offacilitates treatment, prophylaxis, and diagnosis ofdiseases. This antigen is highly resistant to proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from threestrains and from onestrain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of thesurface protein, and antibodies that bind to this protein are also disclosed.

Proteinase K resistant surface protein of neisseria meningitidis

A highly conserved, immunologically accessible antigen at the surface of,organisms. Immunotherapeutic, prophylactic and diagnostic compositions and methods useful in the treatment, prevention an diagnosis of,diseases. A proteinase K resistant,surface protein having an apparent molecular weight of 22 kDa, the corresponding nucleotide and derived amino acid sequences (SEQ ID NO: 1, NO:3, NO:5 and NO:7: SEQ ID NO: 2, NO:4, NO:6, and NO:8), recombinant DNA methods for the production of the,22 kDA surface protein, and antibodies that bind to the,22 kDA surface protein.

Growing community of inventors

Ile Bizard, Canada

Clement Rioux